Filing Details
- Accession Number:
- 0000950170-24-077518
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-25 20:00:02
- Reporting Period:
- 2024-06-21
- Accepted Time:
- 2024-06-25 20:00:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 873303 | Sarepta Therapeutics Inc. | SRPT | Pharmaceutical Preparations (2834) | 930797222 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1959750 | Bilal Arif | 215 First Street Cambridge MA 02129 | Chief Tech Ops Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-06-21 | 6,250 | $0.00 | 31,472 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-06-24 | 2,352 | $164.64 | 29,120 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2024-06-24 | 5,580 | $162.31 | 23,540 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-24 | 1,055 | $163.83 | 22,485 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-24 | 300 | $164.61 | 22,185 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-24 | 700 | $166.10 | 21,485 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-24 | 224 | $167.13 | 21,261 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-25 | 3,898 | $163.23 | 17,363 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance Stock Units | Acquisiton | 2024-06-21 | 6,250 | $0.00 | 6,250 | $0.00 |
| Common Stock | Performance Stock Units | Disposition | 2024-06-21 | 6,250 | $0.00 | 6,250 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 6,250 | No | 4 | A | Direct | ||
| 0 | No | 4 | M | Direct |
Footnotes
- Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.
- Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.25 to $163.21, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.35 to $164.18, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.38 to $164.91, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.69 to $166.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.91 to $167.36, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Billionaire Hedge Funds
